Please login to the form below

Not currently logged in
Email:
Password:

Tabrecta

This page shows the latest Tabrecta news and features for those working in and with pharma, biotech and healthcare.

AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China

AZ, HUTCHMED win first approval for MET inhibitor Orpathys in China

Since then, Tepmetko has received approval in the same patient population from the US Food and Drug Administration (FDA), with Novartis’ MET inhibitor Tabrecta (capmatinib) also winning a US authorisation for

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....